PresVu Eye Drops

In a groundbreaking development in the field of ophthalmology, ENTOD Pharmaceuticals has secured approval from the Central Drugs Standard Control Organisation (CDSCO) for their revolutionary PresVu eye drops, designed to address presbyopia, a common age-related vision impairment affecting millions of individuals in India.

PresVu marks a significant breakthrough as the first-of-its-kind eye drop in India aimed at eliminating the need for reading glasses among individuals grappling with presbyopia. Clinical trials have demonstrated PresVu’s efficacy in enhancing close-up vision within minutes of application, providing temporary relief for up to six hours.

The innovation behind PresVu lies in its dynamic buffer technology, developed through ENTOD Pharmaceuticals’ DSIR-approved R&D facility. This technology allows the eye drops to adjust rapidly to tear pH, ensuring sustained efficacy and safety for long-term use.

Mr. Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals, expressed his enthusiasm, stating, “The approval of PresVu represents a significant milestone in our mission to redefine eye care in India. We are committed to providing accessible and effective solutions to individuals suffering from presbyopia, empowering them to regain visual clarity and independence.”

PresVu offers a promising alternative to traditional interventions like reading glasses, particularly for individuals aged 40 to 55 with mild to intermediate presbyopia. Its transformative potential has been praised by experts in the field, including Dr. Vardhaman Kankariya, Director of Asian Eye Hospital, Pune, who emphasized its ability to enhance the quality of life for patients.

As ENTOD Pharmaceuticals prepares for the commercialization of PresVu, they remain dedicated to innovation and excellence in the pharmaceutical industry. PresVu stands poised to revolutionize presbyopia management, offering hope and freedom to millions of individuals nationwide.

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Related News